Clinical aspects for differential diagnosis of Kawasaki disease shock syndrome: a case control study

Woo Young Park, Sang Yun Lee*, Gi Beom Kim, Mi Kyoung Song, Hye Won Kwon, Eun Jung Bae, Eun hwa Choi and June Dong Park

Abstract

Background: Because of the absence of a specific diagnostic test and pathognomonic clinical features, physicians must rely on the presence of specific clinical criteria and laboratory data that support the diagnosis of KD. To help clinicians distinguish KD, KDSS, septic shock, and TSS earlier, we suggest differential diagnosis and treatment guideline.

Methods: Medical records of immunocompetent patients who were admitted to the pediatric department with a diagnosis of KDSS, septic shock or TSS (SS group) were retrospectively reviewed. In addition, KD patients were selected by seasonal matching to each case of KDSS patient by date of admission (± 2 weeks).

Results: There were 13 patients with KDSS, 35 patients with SS group, and 91 patients with KD. In comparison between KDSS and septic shock group, KDSS group had significantly higher rate of coronary aneurysm incidence, and higher left ventricle dysfunction rate. In comparison between KDSS and TSS, patients with KDSS had a significantly higher erythrocyte sedimentation rate (ESR) and significantly lower creatinine. Receiver operation characteristic curve revealed that the optimal ESR cut off value for determining the KDSS was 56.0 (sensitivity 75.0%, specificity of 100.0%) and the optimal creatinine cut off value for determining the TSS was 0.695 (sensitivity 76.9%, specificity 84.6%).

Conclusions: Clinical symptoms, laboratory finding, echocardiography, and culture studies can be used to differentiate KD, KDSS, septic shock and TSS.

Keywords: Kawasaki disease shock syndrome, Kawasaki disease, Septic shock, Toxic shock syndrome

Background
Kawasaki disease (KD) is an acute systemic inflammatory vasculitis of early childhood, predominantly involving medium-sized arteries [1]. About 15–25% of untreated children will develop coronary artery abnormalities [2]. Early detection and prompt initiation of therapy with high dose intravenous immunoglobulin (IVIG) plus aspirin can reduce the incidence of serious coronary artery complications. Therefore, accurate and timely diagnosis of KD is critical. However, because of the absence of a specific diagnostic test and pathognomonic clinical features, physicians must rely on the presence of specific clinical criteria and laboratory data that support the diagnosis of KD, while excluding other illnesses that could mimic the disease [3].

As the COVID-19 pandemic continues, there have been reports of multi-system inflammatory syndrome in children (MIS-C) that shares clinical features with KD [4]. Recognition of sudden increase of severe Kawasaki-
Kawasaki disease is the most common vasculitis of childhood and is a significant cause of morbidity and mortality. The typical clinical presentation includes fever of at least five days duration and at least four of the following five features: bilateral bulbar conjunctivitis, strawberry tongue, periorbital edema, polymorphous rash, and cervical lymphadenopathy (≥ 1.5 cm in diameter), usually unilateral. A diagnosis of incomplete or atypical KD was used for patients with a history of fever lasting for more than five days who had less than four of the five typical clinical features of KD but showed evidence of coronary artery lesion on echocardiography or compatible laboratory findings suggested by AHA [7]. KDSS was defined as a patient with KD complicated by hypotension without evidence of infection [5]. Hypotension was defined as a systolic blood pressure < 5th percentile for a patient’s age. All patients with TSS were diagnosed by infection specialists using the diagnostic criteria provided by the Centers for Disease Control and Prevention (Supplement Table 1) [8]. Septic shock was defined as sepsis and cardiovascular organ dysfunction. Cardiovascular organ dysfunction means hypotension (< 5th percentile for age) despite > 40 ml/kg fluid bolus in 1 h or vasoactive requirement to maintain blood pressure despite > 40 ml/kg fluid bolus in 1 h or two or more signs of abnormal perfusion (increased lactate, metabolic acidosis, decreased urine output (< 0.5 mL/kg/hr), capillary refill > 5 s) [9]. Organ damage was defined as damage in major organs including brain, heart, lung, liver, and kidney due to hypoperfusion and sequential organ failure assessment score was used as an index [10]. The coronary artery aneurysm was defined as Z score ≥ 2.5. In the present study, patients with septic shock and TSS were assigned into the septic shock (SS) group.

Methods

Patient selection
A computerized search program was used to search for patients diagnosed with KD or KDSS or SS that occurred in immunocompetent patients from January 2004 to August 2019. These patients were classified into three groups: KDSS group, KD group, and SS group. 13 patients satisfied the KDSS criteria [5]. In KD group, control subjects were chosen for each case patient and matched to its control by date of admission (± 2 weeks) as the matching factor to control for the possibility of seasonal variation. Patients with incomplete KD and refractory KD were also included in the KD group. Ninety-one patients met the inclusion criteria [6]. To search for patients with septic shock group, we searched “Septic shock” and “Toxic shock syndrome” from discharge records and immunocompromised patients were excluded. A total of 29 patients met the inclusion criteria for the septic shock or toxic shock syndrome. This study used clinical data retrieved from Seoul National University Hospital Patients Research Environment system. This study was approved by the Institutional Review Board of the Seoul National University Hospital (IRB number: 1910–051-1068, approved date: Oct 14th, 2019).

Definitions
Diagnosis of KD was based on the diagnostic criteria provided by the American Heart Association (AHA) [7]. The diagnostic criteria were the presence of a fever lasting for at least five days and at least four of the following five typical clinical features of KD: bilateral bulbar conjunctival injection without exudate, erythema and cracking of lips, strawberry tongue, and/or erythema of oral and pharyngeal mucosa, polymorphous rash and cervical lymphadenopathy (≥ 1.5 cm in diameter), usually unilateral. A diagnosis of incomplete or atypical KD was used for patients with a history of fever lasting for more than five days who had less than four of the five typical clinical features of KD but showing evidence of coronary artery lesion on echocardiography or compatible laboratory findings suggested by AHA [7]. KDSS was defined as a patient with KD complicated by hypotension without evidence of infection [5]. Hypotension was defined as a systolic blood pressure < 5th percentile for a patient’s age. All patients with TSS were diagnosed by infection specialists using the diagnostic criteria provided by the Centers for Disease Control and Prevention (Supplement Table 1) [8]. Septic shock was defined as sepsis and cardiovascular organ dysfunction. Cardiovascular organ dysfunction means hypotension (< 5th percentile for age) despite > 40 ml/kg fluid bolus in 1 h or vasoactive requirement to maintain blood pressure despite > 40 ml/kg fluid bolus in 1 h or two or more signs of abnormal perfusion (increased lactate, metabolic acidosis, decreased urine output (< 0.5 mL/kg/hr), capillary refill > 5 s) [9]. Organ damage was defined as damage in major organs including brain, heart, lung, liver, and kidney due to hypoperfusion and sequential organ failure assessment score was used as an index [10]. The coronary artery aneurysm was defined as Z score ≥ 2.5. In the present study, patients with septic shock and TSS were assigned into the septic shock (SS) group.

Data collection
For all patients with KD, we accessed the following retrospectively collected data: demographic data (age, gender, associated symptoms and number of days of fever at presentation), laboratory values (white blood cell and differential counts, platelet count, erythrocyte sedimentation rate (ESR), and concentrations of hemoglobin, C-reactive protein (CRP), aspartate aminotransferase (AST), alanine aminotransaminase (ALT), and γ-glutamyl transpeptidase (GGT), creatinine, blood urea nitrogen (BUN), albumin, electrolytes), laboratory evaluations of coagulation function, response to IVIG, oral prednisolone, methylprednisolone pulse therapy, and infliximab, and echocardiographic data. The laboratory data were compared to the worst values between 3 groups.

Statistical analysis
All data analyses were performed using SPSS statistics 25.0 (IBM, Armonk, NY, USA). Data is presented as median and ranges if not normally distributed. Not normally distributed data was compared between groups using the Mann-Whitney test, Fisher’s exact test, or Chi-square test. One-way ANOVA was performed for continuous variables if normally distributed. Kruskal-Wallis test was used to compare the laboratory data.
among more than two groups. Area under the ROC (receiver operating characteristic) curve was used as an accuracy index for the diagnosis of KDSS. As appropriate, \( p < 0.05 \) was considered significant.

**Results**

From January 2004 to August 2019, 13 patients were diagnosed as a KDSS. Over the same time, 13 patients were admitted with a diagnosis of TSS and 16 patients were admitted with a diagnosis of septic shock. In addition, 91 patients were treated as KD. Demographics and clinical characteristics for KDSS group and control groups are shown in supplement Table 2.

All patients in the KDSS and KD group, and 17 of 29 patients in the SS group received an echocardiographic assessment. Laboratory values and ejection fraction for KDSS group and control groups are shown in Fig. 1 and supplement Table 3. Kawasaki features, associated symptoms and treatment for KDSS group and control groups are shown in supplement Table 4.

**KDSS vs. KD**

Demographics and clinical characteristics of patients with Kawasaki disease shock syndrome and Kawasaki disease are shown in Table 1. Patients with KDSS had a significantly older age \( (p = 0.000) \), longer fever duration \( (p = 0.002) \), longer hospital day \( (p = 0.000) \), longer ICU admission days \( (p = 0.000) \), and higher rate of using inotropic drugs \( (p = 0.000) \) than patients with KD. However, there were no significant differences in sex-distribution between the two groups.

Kawasaki features and associated symptoms of Kawasaki disease shock syndrome and Kawasaki disease are shown in Table 2. There was no statistically significant difference in Kawasaki features between KDSS and KD groups. Patients in the KDSS group had significantly higher gastrointestinal symptoms \( (p = 0.000) \), respiratory symptoms \( (p = 0.000) \), systemic pain \( (p = 0.000) \), pleural effusion \( (p = 0.00) \), and organ damage \( (p = 0.000) \) than those in the KD group.

**Table 1** Demographics and clinical characteristics of patients with Kawasaki disease shock syndrome and Kawasaki disease (continuous variables were described as median and range)

|                      | KDSS \((n=13)\) | KD \((n=91)\) | \(P\) value |
|----------------------|-----------------|---------------|-------------|
| Age, (years)         | 5.1 (0.5–10.6)  | 2.3 (0.2–8.4) | 0.000       |
| Male (%)             | 46.2% (6/13)    | 58.2% (53/91) | 0.411       |
| Fever duration (days)| 11 (8–23)       | 8 (3–29)      | 0.002       |
| Total hospital day (days) | 18 (6–31)   | 6 (3–18)      | 0.000       |
| Follow up duration (months) | 10 (1–105) | 13 (0–175)    | 0.723       |
| ICU care (%)         | 53.8% (7/13)    | 0.0% (0/91)   | 0.000       |
| ICU care duration (days) | 4 (0–11)     | 0             | 0.000       |
| Inotropic drugs (%)  | 92.3% (12/13)   | 1.1% (1/91)   | 0.000       |
| Respiratory support  |                 |               |             |
| - No support         | 30.8% (4/13)    | 100% (91/91)  | 0.000       |
| - Oxygen delivery    | 53.8% (7/13)    | 0.0% (0/91)   | 0.000       |
| - Mechanical ventilation | 15.4% (2/13) | 0.0% (0/91)   | 0.015       |
| Mortality (%)        | 0.0% (0/13)     | 0.0% (0/91)   | 0.000       |

KDSS Kawasaki disease shock syndrome, KD Kawasaki disease, SS Septic shock and toxic shock syndrome, ICU Intensive care unit

**Fig. 1** Comparison of Age, Fever duration, Laboratory Results and Ejection fraction in 3 Different Patient Groups. Statistics were calculated with GraphPad Prism software. Horizontal lines represent median values for each group and vertical lines represent interquartile range. *, **: statistically significant, \( p < 0.05 \), as determined by the Kruskal-Wallis test. ns: not significant
Diagnosis of Kawasaki disease shock syndrome and Kawasaki disease are shown in Table 3. The KD group had significantly higher rate of initial diagnosis of KD than those in the KDSS group and KDSS group initially showed only 1–2 of typical Kawasaki symptoms. However, 3 or more symptoms were seen in all patients eventually. In addition, patients in the KDSS group had significantly higher IVIG resistance rate than those in the KD group.

Compared to those in the KD group, patients in the KDSS group had lower hemoglobin level ($p = 0.000$), lower platelet counts ($p = 0.00$), higher C-reactive protein level ($p = 0.000$), higher total bilirubin level ($p = 0.012$), higher creatinine level ($p = 0.001$), higher BUN level ($p = 0.000$), lower albumin level ($p = 0.00$), and lower sodium level ($p = 0.000$) (Fig. 1, supplementary Table 3).

KDSS vs SS group
Demographics and clinical characteristics of patients with Kawasaki disease shock syndrome and septic shock group are shown in Table 4. There were no significant differences in sex-distribution, age, fever duration, total hospital day, ICU admission days, or rate of using inotropic drugs between the two groups.

Kawasaki features and associated symptoms of patients with Kawasaki disease shock syndrome and septic shock group are shown in Table 5. Patients with KDSS had significantly higher rate of conjunctival injection ($p = 0.000$), oropharyngeal changes ($p = 0.000$), cervical lymphadenopathy ($p = 0.000$), and extremity changes ($p = 0.001$) than patients with SS group. In addition, patients with KDSS had a significantly higher rate of respiratory symptoms ($p = 0.033$) and pleural effusion ($p = 0.033$) than patients with SS group.

Diagnosis and treatment of Kawasaki disease shock syndrome and septic shock group are shown in Table 6. Patients with KDSS had significantly higher rates of usage 2nd IVIG ($p = 0.000$), and methylprednisolone pulse therapy ($p = 0.002$) than patients with SS group.

### Table 2 Kawasaki features and associated symptoms of Kawasaki disease shock syndrome and Kawasaki disease

|                          | KDSS ($n=13$)   | KD ($n=91$)   | $P$ value |
|--------------------------|-----------------|--------------|-----------|
| **Kawasaki features**    |                 |              |           |
| Conjunctival injection   | 92.3% (12/13)   | 91.2% (83/91)| 1.000     |
| Oropharyngeal changes    | 84.6% (11/13)   | 81.3% (74/91)| 1.000     |
| Polymorphous rash        | 76.9% (10/13)   | 84.6% (77/91)| 0.442     |
| Cervical lymphadenopathy | 69.2% (9/13)    | 44.0% (40/91)| 0.088     |
| Extremity changes        | 92.3% (12/13)   | 67.0% (61/91)| 0.102     |
| **Associated symptoms**  |                 |              |           |
| Gastrointestinal symptoms| 84.6% (11/13)   | 26.4% (24/91)| 0.000     |
| Respiratory symptoms     | 76.9% (10/13)   | 9.9% (9/91)  | 0.000     |
| Neurologic symptoms      | 15.4% (2/13)    | 2.2% (2/91)  | 0.066     |
| Systemic pain            | 53.8% (7/13)    | 3.3% (3/91)  | 0.000     |
| Pleural effusion         | 76.9% (10/13)   | 2.2% (2/91)  | 0.000     |
| Organ damage             | 92.3% (12/13)   | 20.9% (19/91)| 0.000     |

KD: Kawasaki disease, KDSS: Kawasaki disease shock syndrome, SS: Septic shock and toxic shock syndrome

### Table 3 Diagnosis, and treatment of Kawasaki disease shock syndrome and Kawasaki disease

|                          | KDSS ($n=13$) | KD ($n=91$) | $P$ value |
|--------------------------|--------------|-------------|-----------|
| **Diagnosis**            |              |             |           |
| Initial diagnosis of KD  | 23.1% (3/13) | 80.2% (73/91)| 0.000     |
| Complete KD              | 46.2% (6/13) | 67.0% (61/91)| 0.214     |
| Incomplete KD            | 38.5% (5/13) | 29.7% (27/91)| 0.532     |
| **Treatment**            |              |             |           |
| 1st IVIG                 | 84.6% (11/13)| 98.9% (90/91)| 0.041     |
| 2nd IVIG                 | 76.9% (10/13)| 19.8% (18/91)| 0.000     |
| Oral prednisolone        | 7.7% (1/13)  | 11.0% (10/91)| 1.000     |
| Methylprednisolone pulse therapy | 38.5% (5/13) | 11.0% (10/91) | 0.020     |
| Infliximab               | 15.4% (2/13) | 0.0% (0/91) | 0.015     |
| Antibiotics              | 92.3% (12/13)| 15.4% (14/91)| 0.000     |

IVIG: Intravenous immunoglobulin, KD: Kawasaki disease, KDSS: Kawasaki disease shock syndrome, SS: Septic shock and toxic shock syndrome
There was no difference in antibiotic treatment rates between the two groups. 12 of the 13 patients in the KDSS were initially treated with antibiotics as they were indistinguishable from septic shock.

Compared with KDSS patients, patients in septic shock group had higher level of creatinine ($p=0.006$) and lower ESR level ($p=0.008$). However, there were no significant differences in hemoglobin, platelet count, CRP level, liver function, BUN, albumin or sodium level between KDSS and SS groups. In addition, there was no coronary artery aneurysm case in SS group. (Fig. 1, Supplement Table 3).

**Discussion**

Because there is no pathognomonic clinical feature or diagnostic test for KD, patients with KDSS are frequently misdiagnosed. Its clinical presentation may be mistaken for septic shock or TSS, leading to delay in treatment [11]. In COVID-19 pandemic period, cases for MIS-C have been reported and shared clinical features with KD, KDSS, and TSS [4]. Case definitions for emerging inflammatory condition during COVID-19 pandemic from the World Health Organization, Royal College of Pediatrics and Child Health, and Centers for Disease Control and Prevention are similar in many ways to KD [12–14]. Therefore, it has become more important to accurately distinguish among various Kawasaki mimicking diseases.

Considering the symptoms of KDSS that look different from KD and similar symptoms to other diseases such as TSS or MIS-C, the pathophysiological cause becomes curious. Despite 4 decades of investigation, the cause of KD remains unknown [7]. Recently updated three major pathophysiologic components of KD are a genetic predisposition, immunomodulation through both habitual exposures and environmental factors, and contact with the disease trigger or triggers [15]. In this background, exposure to the still unidentified trigger such as SARS-CoV-2 might result in the development of KD in a genetically susceptible child, with at least a partial contribution from immune-modulating factors. Multiple factors may act sequentially or simultaneously as predisposing, immune-modulating, or triggering agents, altering both individual risk as well as the incidence of KD in the population across countries or regions [15]. Recent reports of MIS-C suggest that MIS-C may have a different racial predilection, affecting primarily people of African American, Caribbean, and Hispanic ancestry [4].

| Table 4 Demographics and clinical characteristics of patients with Kawasaki disease shock syndrome and septic shock group (continuous variables were described as median and range) |
|----------------------------------|--------|--------|--------|
| **Age** (years) | KDSS (n=13) | SS (n=29) | **P value** |
| 5.1 (0.5–10.6) | 7.6 (3.3–19.9) | 0.185 |
| **Male (%)** | 46.2% (6/13) | 65.5% (19/29) | 0.237 |
| **Fever duration (days)** | 11 (8–23) | 7 (1–114) | 0.068 |
| **Total hospital day (days)** | 18 (6–31) | 13 (7–225) | 0.419 |
| **Follow up duration (months)** | 10 (1–105) | 2.5 (0–119) | 0.124 |
| **ICU care (%)** | 53.8% (7/13) | 62.1% (18/29) | 0.616 |
| **ICU care duration (days)** | 4 (0–11) | 3 (0–20) | 0.591 |
| **Inotropic drugs (%)** | 92.3% (12/13) | 86.2% (25/29) | 0.153 |
| **Respiratory support** | | | |
| - No support | 30.8% (4/13) | 48.3% (14/29) | 0.289 |
| - Oxygen delivery | 53.8% (7/13) | 10.3% (3/29) | 0.005 |
| - Mechanical ventilation | 15.4% (2/13) | 41.4% (12/29) | 0.159 |
| **Mortality (%)** | 0.0% (0/13) | 10.3% (3/29) | 0.540 |

KDSS Kawasaki disease shock syndrome, KD Kawasaki disease, SS Septic shock and toxic shock syndrome, ICU Intensive care unit

**Table 5 Kawasaki features and associated symptoms of Kawasaki disease shock syndrome, and Septic shock group**

| Kawasaki features | KDSS(n=13) | SS (n=29) | **P value** |
|--------------------|-----------|-----|--------|
| Conjunctival injection | 92.3% (12/13) | 10.3% (3/29) | 0.000 |
| Oropharyngeal changes | 84.6% (11/13) | 17.2% (5/29) | 0.000 |
| Polymorphous rash | 76.9% (10/13) | 69.0% (1/29) | 0.722 |
| Cervical lymphadenopathy | 69.2% (9/13) | 3.4% (1/29) | 0.000 |
| Extremity changes | 92.3% (12/13) | 34.5% (10/29) | 0.001 |
| **Associated symptoms** | | | |
| Gastrointestinal symptoms | 84.6% (11/13) | 82.8% (24/29) | 1.000 |
| Respiratory symptoms | 76.9% (10/13) | 41.4% (12/29) | 0.033 |
| Neurologic symptoms | 23.1% (3/13) | 51.7% (15/29) | 0.083 |
| Systemic pain | 53.8% (7/13) | 37.9% (11/29) | 0.335 |
| Pleural effusion | 76.9% (10/13) | 41.4% (12/29) | 0.033 |
| Organ damage | 92.3% (12/13) | 82.8% (24/29) | 0.647 |

KD Kawasaki disease, KDSS Kawasaki disease shock syndrome, SS Septic shock and toxic shock syndrome
The pathophysiology of KDSS is unknown, but it is hypothesized that the “overexpression” of proinflammatory cytokines, in combination with an intense and systemic inflammation, might lead to multiple organ damage and failure in KDSS. These clinical and laboratory findings suggest greater underlying inflammation with a more intense systemic vasculitis, capillary leak, and more profound myocardial involvement [1, 5, 11, 16].

Gámez-González et al. [17] reported that patients with KDSS seem to have more gastrointestinal symptom, incomplete presentation, IVIG resistance and worse cardiac outcomes. These findings were also confirmed in our study. In addition, in our study, patients with KDSS seem to have more respiratory symptoms and systemic pain as well.

Because there is no diagnostic test for KD, the diagnosis is made based on patient’s symptoms. However, symptoms of KD do not appear at once and may appear in other diseases such as TSS and septic shock, making it difficult to diagnose. Thus, for many years, studies to distinguish KD from other diseases have been conducted. Zandstra, Judith, et al. [18] reported that combination of plasma markers, myeloid-related protein 8/14, CRP, and human neutrophil-derived elastase may assist in distinguishing KD from other infection. However, in our study, there was no significant difference in CRP between KDSS and SS group. These inflammatory markers are still insufficient to confirm KD and further studies are needed.

Table 6 Diagnosis, and treatment of Kawasaki disease shock syndrome, and Septic shock group

| Diagnosis                  | KDSS (n=13) | SS (n=29) | P value |
|----------------------------|-------------|-----------|---------|
| Initial diagnosis of KD    | 23.1% (3/13) | 0% (0/29) | 0.025   |
| Complete KD                | 46.2% (6/13) | 0% (0/29) | 0.000   |
| Incomplete KD              | 38.5% (5/13) | 3.4% (1/29) | 0.007   |
| Treatment                  |             |           |         |
| 1st IVIG                   | 84.6% (11/13) | 51.7% (15/29) | 0.084   |
| 2nd IVIG                   | 76.9% (10/13) | 17.2% (5/29) | 0.000   |
| Oral prednisolone pulse therapy | 38.5% (5/13) | 0.0% (0/29) | 0.002   |
| Infliximab                 | 15.4% (2/13) | 0.0% (0/29) | 0.091   |
| Antibiotics                | 92.3% (12/13) | 100.0% (29/29) | 0.310   |

IVIG Intravenous immunoglobulin, KD Kawasaki disease, KDSS Kawasaki disease shock syndrome, SS Septic shock and toxic shock syndrome

Fig. 2 Comparison of Age, Fever duration, Laboratory Results and Ejection fraction in 4 Different Patient Groups. Statistics were calculated with GraphPad Prism software. Horizontal lines represent median values for each group and vertical lines represent interquartile range. *, **: statistically significant, (p < 0.05), as determined by the Kruskal-Wallis test. ns: not significant
In actual clinical trials, it was difficult to distinguish between KDSS and TSS. Therefore, we studied the differential diagnosis between KDSS and TSS and performed analysis among subgroups. In comparison of clinical manifestations between KDSS and TSS, no patients with TSS showed conjunctival injection or cervical lymphadenopathy, which could be the points of differential diagnosis. In laboratory tests, highest ESR and creatinine level showed significant difference and possibility as useful marker for differential diagnosis in two groups. (Figs. 2 and 3) These results are novel findings, and different from previous studies [1]. Since the diagnostic criteria for TSS include elevated creatinine, it is not surprising that the TSS group has a significantly
higher creatinine level. Since ESR level is proportional to the intensity of inflammation, it is estimated that more severe inflammatory immune response occurs in KDSS.

According to our comparison among each groups, specific symptoms and laboratory findings of each group are summarized in Supplement Table and Figure. Based on our clinical experiences, KDSS and SS group had many common findings. However, the KDSS group had Kawasaki symptoms, coronary dilation, and left ventricle dysfunction. These findings can help us differentiate KDSS from SS group. Based on our results, we suggested a differential diagnosis and treatment guideline for KDSS (Fig. 4).

Study limitations
This study has several limitations. Our study was retrospective in nature and our case number was too small to analyze independent risk factors. This was a case-control study. KD patients were selected by seasonal matching to each case patient based on the date of admission within two weeks before and after. In addition, some patients were diagnosed by clinical manifestations. Thus, there could be a possibility of patient-selection bias.

Conclusions
KDSS should be considered for patients with fever, Kawasaki symptoms, and hypotension. Diagnosis and treatment for patients with KDSS may be more complicated because atypical type, gastrointestinal, respiratory, and neurological symptoms, and treatment resistant type are more common. Clinical symptoms, laboratory finding, echocardiography, and serology or culture studies can be used to differentiate KDSS, SS and TSS. This study also suggested a guideline for diagnosis and treatment of KDSS.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12887-020-02488-w.

Additional file 1: Supplement Table 1. Centers for Disease control and prevention TSS Diagnostic Criteria. Supplement Table 2. Demographics and clinical characteristics of patients with Kawasaki disease shock syndrome, Kawasaki disease, Septic shock and Toxic shock syndrome. (continuous variables were described as median and range).

Supplement table 3. Laboratory and Echocardiographic characteristics of patients with Kawasaki disease shock syndrome, Kawasaki disease, Septic shock and Toxic shock syndrome. Supplement Table 4. Symptoms, diagnosis, and treatment of, Kawasaki disease shock syndrome, Kawasaki disease, Septic shock and Toxic shock syndrome.

Additional file 2: Supplement Figure. Specific symptoms and laboratory findings of each group. AKI = Acute kidney injury, CAL = Coronary artery lesion, ESR = Erythrocyte sediment rate, LV = Left ventricle, GI = Gastrointestinal, GOT = Glutamic oxalacetic transaminase, Cr = Creatinine, BUN = Blood urea nitrogen, HD=Hospital day, ICU= Intensive care unit, KD = Kawasaki disease, KDSS = Kawasaki disease shock syndrome, SS group: Septic shock or toxic shock syndrome; TSS: Toxic shock syndrome.

Abbreviations
AHA: American Heart Association; AST: Aspartate aminotransferase; ALT: Alanine aminotransaminase; BUN: Blood urea nitrogen; CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; GGT: γ-glutamyl transpeptidase; IVIG: Intravenous immunoglobulin; ICU: Intensive care unit; KD: Kawasaki disease; KDSS: Kawasaki disease shock syndrome; MIS-C: Multi-system inflammatory syndrome in children; SS group: Septic shock or toxic shock syndrome; TSS: Toxic shock syndrome

Acknowledgements
Not applicable.

Authors’ contributions
WYP: He is first author of this manuscript. He designed this study, analyzed and interpreted data, and drafted the manuscript and finally approved for submission. GBK, MKS, HWK, EJB, EHC and JDP. They all analyzed and interpreted data and revised the manuscript and finally approved for submission. SYL: He is corresponding author of this manuscript. He designed this study and analyzed and interpreted data, and revised the manuscript and finally approved for submission.

Funding
This work received no financial support.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The ethics committee of the Institutional Review Board of the Seoul National University Hospital approved this retrospective study (IRB number: 1910–051–1068, approved date: Oct 14th, 2019) and we could access the medical records data with this approval. Given the retrospective and grave nature of our study, the need for retrospective parental consent was waived by the Institutional Review Board of the Seoul National University Hospital.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 9 September 2020 Accepted: 22 December 2020

Published online: 08 January 2021

References
1. Lin Y-J, Cheng M-C, Lo M-H, Chien S. Early differentiation of Kawasaki disease shock syndrome and toxic shock syndrome in a pediatric intensive care unit. J Pediatr Infect Dis. 2015;34(11):1163–7.
2. Singh S, Sharma D, Bhattach S, Phillips S. Recent advances in Kawasaki disease–proceedings of the 3rd Kawasaki disease summit, Chandigarh, 2014. Indian J Pediatr. 2016(831):47–52.
3. Yun SH, Yang NR, Park SJ. Associated symptoms of Kawasaki disease. Kcj. 2011;41(7):394–8.
4. Whittaker E, Bamford A, Penny J, Kafou M, Jones CE, Shah P, et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2. Jama. 2020. https://doi.org/10.1001/jama.2020.10369.
5. Kanegaye JT, Wilder MS, Molkara D, Frazer JR, Panchari J, Tremoulet AH, et al. Recognition of a Kawasaki disease shock syndrome. Pediatrics. 2009;123(5):783–9.
6. Dominguez SR, Friedman K, Seewald R, Anderson MS, Willis L, Glode MP. Kawasaki disease in a pediatric intensive care unit: a case-control study. Pediatrics. 2008;122:e786–90.
7. McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term Management of Kawasaki Disease: a scientific statement for health professionals from the American Heart Association. Circulation. 2017;135(17):e927–99.
8. Centers for Disease Control and Prevention. Toxic shock syndrome (other than streptococcal) (TSS). 2011 case definition. 2011. https://www.cdc.gov/
9. Martin K, Weiss SL. Initial resuscitation and management of pediatric septic shock. Minerva Pediatr. 2015;67(2):141.
10. Fujishima S. Organ dysfunction as a new standard for defining sepsis. Inflamm Regen. 2016;36(1):24.
11. Taddio A, Rossi ED, Monasta L, Pastore S, Tommasini A, Lepore L, et al. Describing Kawasaki shock syndrome: results from a retrospective study and literature review. Clin Rheumatol. 2017;36:223–8.
12. World Health Organization. Multisystem inflammatory syndrome in children and adolescents with COVID-19. 2020. https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19/. Accessed 5 Sept 2020.
13. Royal College of Paediatrics and Child Health. Guidance: paediatric multisystem inflammatory syndrome temporally associated with COVID-19. 2020. https://www.rcpch.ac.uk/resources/guidance-paediatric-multisystem-inflammatory-syndrome-temporally-associated-covid-19-pims. Accessed 5 Sept 2020.
14. Centers for Disease Control and Prevention. Emergency preparedness and response: health alert network. 2020. https://emergency.cdc.gov/han/2020/han00432.asp. Accessed 5 Sept 2020.
15. McGriddle BW, Manhiot C. SARS-CoV-2–related inflammatory multisystem syndrome in children: different or shared etiology and pathophysiology as Kawasaki disease? Jama. 2020. https://doi.org/10.1001/jama.2020.10370.
16. Gatterre P, Oualha M, Dupic L, Iserin F, Bodemer C, Lesage F, et al. Kawasaki disease: an unexpected etiology of shock and multiple organ dysfunction syndrome. Intensive Care Med. 2012;38(5):872–8.
17. Gámez-González LB, Murata C, Muñoz-Ramírez M, Yamazaki-Nakashimada M. Clinical manifestations associated with Kawasaki disease shock syndrome in Mexican children. Eur J Pediatr. 2013;172:337–42.
18. Zandstra J, van de Geer A, Tanck MW, van Stijn-Bringas DO, Aarts CE, Dietz SM, et al. Biomarkers for the discrimination of acute Kawasaki disease from infections in childhood. Front Pediatr. 2020;8:355.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.